The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients

2016 ◽  
Vol 20 (1) ◽  
pp. 7-11 ◽  
Author(s):  
M Moschini ◽  
F Soria ◽  
A Briganti ◽  
S F Shariat
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Metastatic Prostate Cancer ◽  
Local Treatment ◽  
Tumor Site ◽  
Primary Tumor Site ◽  
Node Positive ◽  
The Impact

scholarly journals The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma

2019 ◽  
Vol 10 (14) ◽  
pp. 3140-3144 ◽  
Author(s):  
Sang Eun Yoon ◽  
Jung Hoon Kim ◽  
Su Jin Lee ◽  
Jeeyun Lee ◽  
Se Hoon Park ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Primary Tumor ◽  
Tumor Site ◽  
Primary Tumor Site ◽  
Grade 3 ◽  
The Impact

The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 213-213
Author(s):  
Sang Eun Yoon ◽  
Jung Hoon Kim ◽  
Joon Young Hur ◽  
Su Jin Lee ◽  
Jeeyun Lee ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Neuroendocrine Carcinoma ◽  
Primary Tumor ◽  
Medical Center ◽  
Progression Free Survival ◽  
Complete Response ◽  
Tumor Site ◽  
Primary Tumor Site ◽  
Significant Difference ◽  
The Impact

213 Background: Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a heterogeneous disease in terms of embryonic origin, aggressiveness, prognosis, and genomic profiling. Data regarding the efficacy of etoposide and cisplatin (EP) as a standard treatment of the primary tumor site in GEP-NEC are limited. Methods: We analyzed 64 patients with histopathologically confirmed metastatic GEP-NEC who received EP at Samsung Medical Center, Seoul, Korea, between January 2010 and January 2018. Based on primary tumor site, outcome of treatment with EP was evaluated. Results: Primary sites included 22 foregut-derived GEP-NECs (stomach, n = 6; duodenum, n = 4; pancreas, n = 12), 4 midgut-derived GEP-NECs, 5 hindgut-derived GEP-NECs of the rectum, 25 GEP-NECs originating from the hepatobiliary (HB) tract, and 12 GEP-NECs involving only intra-abdominal lymph nodes. No patient had a complete response (CR) and 17 had a partial response (PR), resulting in a 27.9% response rate (RR). When evaluating the efficacy of EP based on primary tumor site, the RR was most favorable in GEP-NECs involving only intra-abdominal lymph nodes, followed by GEP-NECs originating from foregut, midgut, HB, and hindgut. However, no statistically significant difference was observed for RR based on primary tumor site (p = 0.821). Similarly, no significant differences were found for progression-free survival (PFS) among patients with GEP-NECs arising from various primary tumor sites. Conclusions: Results from this study showed thatRR and PFS associated with EP treatment were not different based on the primary tumor site in patients with advanced or metastatic GEP-NEC.

scholarly journals The impact of primary tumor site and anti-VEGF therapy in metastatic colorectal cancer

2017 ◽  
Vol 28 ◽  
pp. iii115
Author(s):  
Ana Pissarra ◽  
Mariana Malheiro ◽  
Andreia Coelho ◽  
Ana Plácido ◽  
Ana Martins
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Primary Tumor ◽  
Tumor Site ◽  
Primary Tumor Site ◽  
Anti Vegf ◽  
The Impact

MP50-12 THE IMPACT OF LOCAL TREATMENT ON OVERALL MORTALITY IN PATIENTS DIAGNOSED WITH PRIMARY METASTATIC PROSTATE CANCER

2016 ◽  
Vol 195 (4S) ◽  
Author(s):  
Björn Löppenberg ◽  
Deepansh Dalela ◽  
Patrick Karabon ◽  
Akshay Sood ◽  
Jesse Sammon ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Local Treatment ◽  
The Impact ◽  
Overall Mortality

scholarly journals Clinical, Biologic, and Prognostic Differences on the Basis of Primary Tumor Site in Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project

2014 ◽  
Vol 32 (28) ◽  
pp. 3169-3176 ◽  
Author(s):  
Kieuhoa T. Vo ◽  
Katherine K. Matthay ◽  
John Neuhaus ◽  
Wendy B. London ◽  
Barbara Hero ◽  
...  
Keyword(s):  
Primary Tumor ◽  
Odds Ratio ◽  
Adjusted Odds Ratio ◽  
Risk Group ◽  
Primary Site ◽  
Adrenal Tumors ◽  
Mycn Amplification ◽  
Tumor Site ◽  
Primary Tumor Site ◽  
The Impact

PurposeNeuroblastoma (NB) is a heterogeneous tumor arising from sympathetic tissues. The impact of primary tumor site in influencing the heterogeneity of NB remains unclear.Patients and MethodsChildren younger than age 21 years diagnosed with NB or ganglioneuroblastoma between 1990 and 2002 and with known primary site were identified from the International Neuroblastoma Risk Group database. Data were compared between sites with respect to clinical and biologic features, as well as event-free survival (EFS) and overall survival (OS).ResultsAmong 8,369 children, 47% had adrenal tumors. All evaluated clinical and biologic variables differed statistically between primary sites. The features that were > 10% discrepant between sites were stage 4 disease, MYCN amplification, elevated ferritin, elevated lactate dehydrogenase, and segmental chromosomal aberrations, all of which were more frequent in adrenal versus nonadrenal tumors (P < .001). Adrenal tumors were more likely than nonadrenal tumors (adjusted odds ratio, 2.09; 95% CI, 1.67 to 2.63; P < .001) and thoracic tumors were less likely than nonthoracic tumors (adjusted odds ratio, 0.20; 95% CI, 0.11 to 0.39; P < .001) to have MYCN amplification after controlling for age, stage, and histologic grade. EFS and OS differed significantly according to the primary site (P < .001 for both comparisons). After controlling for age, MYCN status, and stage, patients with adrenal tumors had higher risk for events (hazard ratio, 1.13 compared with nonadrenal tumors; 95% CI, 1.03 to 1.23; P = .008), and patients with thoracic tumors had lower risk for events (HR, 0.79 compared with nonthoracic; 95% CI, 0.67 to 0.92; P = .003).ConclusionClinical and biologic features show important differences by NB primary site, with adrenal and thoracic sites associated with inferior and superior survival, respectively. Future studies will need to investigate the biologic origin of these differences.

Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis

2018 ◽  
Vol 73 (3) ◽  
pp. 452-461 ◽  
Author(s):  
Thomas Seisen ◽  
Malte W. Vetterlein ◽  
Patrick Karabon ◽  
Tarun Jindal ◽  
Akshay Sood ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Local Treatment ◽  
Initial Diagnosis ◽  
Pelvic Lymph Node ◽  
Node Positive ◽  
Node Positive Disease ◽  
Lymph Node Positive
Sign in / Sign up

Export Citation Format

Share Document